SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative interest as traders discuss its potential role in Japan's expanding IoT and tokenized data ecosystem. The community remains deeply divided, with long-term holders pointing to long-term accumulation and partnership rumors, while skeptics emphasize the lack of recent price momentum and competitive shifts within the project's leadership.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy community is actively mobilizing around the MULN crypto token, with supporters pushing for a resurgence similar to previous market rallies while critics warn of pump-and-dump mechanics. The conversation is heavily driven by retail coordination on social platforms, alongside community calls for new buying pressure to sustain the token's momentum.

ARK ETF Trust - ARK Space & Defense Innovation ETF

ARK Space Exploration & Innovation ETF

The ARK Space Exploration & Innovation ETF is generating intense community interest driven by anticipation surrounding a potential SpaceX IPO and the broader, long-term growth trajectory of the space sector. Investors are actively debating the fund's strategy and composition, viewing it as a strategic, albeit volatile, play on the future of space infrastructure, defense technology, and AI integration.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain is generating significant community conversation as investors debate the impact of institutional developments like the EU's Digital Product Passport and the Hayabusa protocol upgrade on long-term utility. While many users express frustration over stagnant price action and declining market cap ranking, the community remains divided between those accumulating through market volatility and those skeptical of the foundation's recent management and transparency.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is currently drawing significant attention from investors as it aggressively scales its 'physical AI' infrastructure and secures major partnerships, most notably with Volkswagen, to integrate its autonomous driving software. The community remains deeply divided, with bulls pointing to these high-tech milestones and global expansion plans as evidence of long-term value, while bears focus on delivery volatility and ongoing downward price pressure from institutional trading patterns.

Ascend is a prediction perpetuals platform that allows you to trade prediction markets with up to 100x leverage. Ascend is multi-chain, ZK-settled on Midnight, secured by Cardano. Ascend turns prediction markets into real-time, tradable markets. Instead of simply betting on outcomes and waiting for resolution, users can trade the probability of events (like BTC hitting $100K) using a perpetual-style engine, entering and exiting positions anytime. Trades are executed off-chain for speed and then batch-settled on Midnight using zero-knowledge (ZK) proofs, giving users a seamless experience with strong on-chain guarantees. This creates a more dynamic, liquid, and capital-efficient way to trade information and belief.

Project Ascend

Project Ascend is capturing significant investor attention as the community anticipates a major rally following the upcoming main-net launch and current consolidation phase. Market participants are actively buzzing about the project's growth potential, framing the current price action as a key accumulation opportunity.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

The VVV (Venice Token) community is highly bullish, driven by the AI narrative, upcoming token burns, and a perceived supply crunch due to its low circulating supply and staking activity. Traders are actively discussing the token's potential to reach double-digit price levels as a decentralized AI play, often citing new platform features and the potential for a major exchange listing as catalysts for future price appreciation.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

The GIGA community is actively discussing the coin's long-term potential as an asymmetric opportunity, fueled by ongoing engagement with the Giga Fitness brand and recent real-world visibility. While some investors remain cautious about volatility, many are advocating for a disciplined dollar-cost averaging strategy, drawing parallels to previous market cycles and highlighting the strength of the GigaChad meme culture.

$VIX. The volatility index of the SPX.  The volatility of the SPX compressed, distilled, and put on the blockchain. That's the VIX777. Each token is meticulously and mathematically designed to profit from variation. At the VIX, utility IS volatility.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced,   VIX777 is a memecoin. It is completely useless and fulfills no purpose or utility. Partaking in the community in any way has no expectation of profit and is done for entertainment purposes only.

VIXCO

Investors are closely tracking VIX as they debate whether the index is signaling a necessary market correction or offering a buying opportunity amid heightened political uncertainty and global tensions. Community sentiment is sharply divided, with many traders monitoring the 20 level as a key threshold to determine whether broader equity momentum will sustain its run or face a significant volatility surge.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is trending as investors react to the company's aggressive strategic pivot, which includes a significant workforce reduction, the departure of its CEO, and the deprioritization of its lead clinical asset, luveltamab tazevibulin, to conserve capital. While the company is refocusing on its next-generation ADC pipeline with a strengthened cash runway into 2026, the community is actively debating the implications of shelving a late-stage asset versus the long-term potential of the platform-based research approach.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ATRA Crosses Above Average Analyst Target

In recent trading, shares of Atara Biotherapeutics Inc (Symbol: ATRA) have crossed above the average analyst 12-month target price of $9.33, changing hands for $9.93/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade...

<ul class="summary-bullets"><li>Atara is jointly developing the drug with Pierre Fabre Pharmaceuticals.</li><li>The FDA stated that a single-arm study using a historical control group could support a future marketing application.</li><li>FDA had rejected an initial application submitted by Atara in January 2026, raising concerns about the trial design and analysis.</li></ul>Shares of Atara Biotherapeutics (ATRA) surged more than 43% in morning trade on Thursday, recording their biggest single-day gains in more than two years, after the biotech firm announced a promising update from the U.S. Food and Drug Administration (FDA) tied to its experimental blood cancer therapy.<a href="https://stocktwits.com/symbol/ATRA">ATRA shares</a> also breached the 100-day moving average (100-DMA) for the first time in nearly four months.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AATRA"><img src="https://news.stocktwits-cdn.com/ATRA_jpg_7fc3a2b23b.webp" alt="ATRA.jpg"></a>Source: TradingView<h2 class="st-heading-2">FDA Talks Signal Resubmission Hopes For ATRA’s Immunotherapy</h2>Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application (BLA) for Tabelecleucel. The drug is used for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD).The update followed a recent Type A meeting between the FDA, Atara, and its partner, Pierre Fabre Pharmaceuticals, after the agency issued a Complete Response Letter (CRL) earlier this year, stating that it could not approve the application in its current form.However, the FDA has now stated that a single-arm study using a historical control group could support a future marketing application. Pierre Fabre plans to include updated results from its Phase 3 study, including additional patient data and longer follow-up, as part of the resubmission package.Atara and Pierre Fabre are jointly developing the drug.<h2 class="st-heading-2">Why Did FDA Reject ATRA’s Initial Application?</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/atra-rises-on-pushing-for-meeting-with-fda-on-rare-disease-drug-rejection/cZdeli8RIP1">previously</a> declined to approve Tabelecleucel, stating the company’s study did not provide enough evidence for accelerated approval and raised concerns about the trial design and analysis.Pierre Fabre responded to the agency, providing additional explanations and arguing that the study was properly controlled and suitable to support the application. The company also submitted updated long-term efficacy data, along with supportive development and European post-marketing data, for a potential resubmission.<h2 class="st-heading-2">Retail Skeptical About ATRA’s Rally</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.However, one user stated the news did not justify the rally.<stembedurl>https://stocktwits.com/robanbieber/message/652581236</stembedurl>Another user called ATRA’s chart setup “neutral” and saw support between $6.50 and $7.<stembedurl>https://stocktwits.com/independentresearch1/message/652578353</stembedurl>ATRA shares have been under heavy selling pressure this year, slumping nearly 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-bulls-shrug-off-earnings-loss-retail-traders-eye-a-crucial-fda-deadline/cZXbg96ReQT">IBRX Bulls Shrug Off Earnings Loss -- Retail Traders Eye A Crucial FDA Deadline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

 Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

Equity

Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

Healthcare Disruption, AI Biologics, and Wall Street Upgrades Ignite a Midday Market Surge

Healthcare innovators are pushing the markets today. $TGNT, $AGL, $ATRA, $ASBP

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to...

The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA

The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA The Gross Law Firm Reminds Atara...

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire...

ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP...

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA Pomerantz Law Firm Announces the Filing of a Class Action Against Atara...

Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky PR Newswire NEW YORK, April 29, 2026 NEW YORK, April 29, 2026...

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

ATRA
Atara Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest ATRA News

ATRAAtara Biotherapeutics Inc